MoS launches Ayush Anudan Portal under Ayush Grid Initiative (See 'Corp Brief') IPR - Sec 17 of Trade Marks Act does not prevent protection of prominent part of composite mark where that part is distinctive: HC (See 'Legal Desk') Coal Production commences from Urtan and Dhirauli Mines in MP (See 'Corp Brief') Govt's TEAM Initiative empowering Small Businesses through Digital Commerce Enablement (See 'Corp Brief') PMLA - Provisional attachment not invalidated due to lack of competency of officer; amended provisions do not apply to transactions prior to 2016 amendment if property continues to be held: SAFEMA (See 'Legal Desk') MoRD charts roadmap for Women-Led Rural Marketing Ecosystems (See 'Corp Brief') Pharmacopoeia Commission organizes 5-Day Capacity Building Training (See 'Corp Brief') Saurabh Vijay assumes charge as CEO of Unique Identification Authority of India (See 'Corp Brief') Companies Act - Appellant company directed to change its name where it significantly resembles the name of a pre-existing company and may cause confusion: HC (See 'Legal Desk') Minister reviews technology-led underground mining, integrated smelting operations (See 'Corp Brief') Scientific Steering Committee Meeting on National One Health Mission Held in New Delhi (See 'Corp Brief') Govt launches campaign to reduce edible oil consumption (See 'Corp Brief') PMLA - Provisional attachment unsustainable when Initiating Officer fails to establish source of consideration & beneficial ownership as per Section 2(9)(A): SAFEMA (See 'Legal Desk') HM inaugurates 'Million Minds Tech Park' and 'GREMI City Campus' in Ahmedabad (See 'Corp Brief') Amit Shah inaugurates State-of-the-Art Milk Processing Plant of Madhur Dairy (See 'Corp Brief') Experts Discuss Yoga for Youth and Mental Wellness in Digital Era (See 'Corp Brief') Misc - RBI circular dated June 07, 2019 on 'Prudential Framework for Resolution of Stressed Assets' was policy decision taken by expert body in larger public interest: HC (See 'Legal Desk') GeM continues to support Digital Public Procurement System (See 'Corp Brief') Ministry of Education reviews strategy for mainstreaming Out-of-School children (See 'Corp Brief') Misc - NBFC cannot reposses financed vehicle through coercive means, without adherence to due process of law and in violation of RBI recovery guidelines: HC (See 'Legal Desk') Supreme Court lays down scenarios for lifting of Doctrine of Corporate Veil (See 'CORP EINSICHTf')

Print

India Pharma 2026: Spotlight on Policy, Regulation, AI and CRDMO

Published: Apr 14, 2026

By TIOLCorplaws News Service

NEW DELHI, APR 14, 2026: THE first day of the 9th India Pharma 2026 witnessed four high-impact plenary sessions that brought together policymakers, industry leaders, regulators and technology experts to chart the future of India's pharmaceutical and life sciences ecosystem. The discussions reflected a strong consensus on accelerating innovation through policy support, regulatory transformation and adoption of next-generation technologies.

The inaugural plenary session on "Policy Thrust for Catalysing Innovation", highlighted the urgent need to bridge the gap between policy intent and on-ground execution. Manoj Joshi, Secretary, Department of Pharmaceuticals, emphasised industry-led model for Research and Development, importance of strengthening government lab networks and attuning regulatory model to that of European systems. Rajiv Bahl, Secretary Department of Health Research said though research funding has increased manifold over the last few years, the country needs a Bharat model of R & D with confidence of the market in the innovators and increased trust between industry and academica. Industry leaders echoed the need for increased venture capital participation and co-funding mechanisms to nurture research-driven enterprises, stronger industry-academia integration and underscored the importance of integrated ecosystems to translate early-stage discoveries into global solutions. The session concluded with a strong call to "Discover in India" and position the country as a global innovation hub.

The second plenary session on "Enabling Regulatory Ecosystem to Foster Innovation" focused on creating a predictable, efficient and globally aligned regulatory framework. Dr. Rajeev Singh Raghuvanshi, Drug Controller General of India highlighted the importance of stakeholder consultations in shaping responsive regulatory systems. Industry Experts called for expedited approval pathways, single-window clearance mechanisms and greater global harmonisation to reduce duplication and accelerate patient access. Industry leaders further underlined the need for digital enablement and continuous collaboration between regulators and industry. The session underscored that a future-ready regulatory ecosystem will be critical to unlocking next-generation therapies and strengthening India's global competitiveness.

The third plenary session on "Harnessing AI and Next-Gen Technologies for Disruptive Innovation"   explored the transformative potential of artificial intelligence across the pharmaceutical value chain. Pharma leaders emphasised reimagining processes rather than merely digitising existing systems. They highlighted the growing importance of strong data and technology foundations to enable scalable AI adoption and  stressed the immediate benefits of automation in improving clinical efficiency. The session concluded on a forward-looking note, with experts agreeing that AI will play a pivotal role in accelerating drug discovery, enabling precision medicine and shaping a smarter, innovation-led healthcare ecosystem.

The fourth plenary session on "Unleashing India's CRDMO Potential" brought focus to India's growing role in the global Contract Research, Development and Manufacturing Organization (CRDMO) landscape. The panel noted that India's CRDMO industry, currently valued at around $8 billion, has been growing at a robust pace of 10-12 percent, reflecting strong global outsourcing demand. Industry leaders stressed that speed will be a critical differentiator in scaling India's R&D and manufacturing capabilities, and highlighted the transformative role of AI and digital technologies, including digital twins, in reshaping the CRDMO ecosystem. The session concluded by outlining the strategic priorities required for India to lead the next phase of global growth in complex modalities and outsourced pharma services.

Overall, the plenary sessions on Day 1 of India Pharma 2026 reinforced India's readiness to lead the next phase of global pharmaceutical innovation, driven by policy intent, regulatory agility and technological advancement.

 

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.